The Link Between Hearing Loss and Dementia: What You Need to Know
Hearing loss is possibly a risk factor of cognitive decline.
Unlocking the causes of Alzheimer’s disease is a complex task, but research is continuing to shed light on the role of a particular gene called APOE. APOE, short for apolipoprotein E, is a gene that produces a protein responsible for transporting cholesterol and other fats in the bloodstream. Understanding the function of APOE and its connection to Alzheimer’s was thought to be crucial in unraveling the mechanisms of the disease and developing effective treatments.
Research has revealed that the APOE gene comes in different forms: APOE2, APOE3, and APOE4. Each form has a varying impact on a person’s risk of developing Alzheimer’s. APOE4, in particular, is associated with a higher risk, with individuals carrying one copy of APOE4 having a three-fold increased risk, and those with two copies having a twelve-fold increased risk compared to individuals without the gene variant.
While having the APOE4 gene doesn’t guarantee the development of Alzheimer’s, it is thought to increase susceptibility. It is helpful, though, to keep in mind that research studies have identified lifestyle factors, including diet, exercising the brain, exercising the body, and social connection to be more important in determining dementia risk, than your genetic profile [1]. Research is ongoing about how gene variants influence Alzheimer’s, aiming to pinpoint underlying mechanisms and identify potential therapeutic targets.
By understanding the role of APOE in Alzheimer’s, researchers and healthcare professionals may improve early detection strategies, develop personalized treatment plans, and work towards preventing or delaying the onset of dementia.
The APOE gene comes in different forms: APOE2, APOE3, and APOE4. Each form has a varying impact on a person’s risk of developing Alzheimer’s. APOE2 is considered the least common variant, and research suggests that it may have a protective effect against Alzheimer’s. Studies have shown that individuals with APOE2 have a lower risk of developing the disease compared to those without the gene variant. While the exact mechanisms behind this protective effect are still being investigated, it provides valuable insights into potential therapeutic strategies.
On the other hand, APOE4 is associated with a higher risk of Alzheimer’s and is the most well-studied and significant genetic risk factor for late-onset Alzheimer’s disease. Scientists are actively researching the underlying mechanisms to understand how APOE4 influences the development and progression of the disease.
The exact role of APOE in Alzheimer’s disease is still not fully understood, but researchers have made significant progress in unraveling its involvement. One theory suggests that APOE4 impairs the clearance of beta-amyloid protein, a hallmark of Alzheimer’s, leading to its accumulation in the brain. Beta-amyloid plaques are known to disrupt communication between neurons and trigger inflammation, ultimately contributing to cognitive decline.
In addition to its role in beta-amyloid clearance, APOE is also involved in other processes that may contribute to Alzheimer’s pathology. Studies have shown that APOE4 affects tau protein, another protein associated with Alzheimer’s. Tau protein forms tangles within neurons, leading to the disruption of their normal function. Furthermore, APOE4 has been found to disrupt synaptic plasticity, impair lipid metabolism, and increase neuroinflammation, all of which play critical roles in the development and progression of Alzheimer’s disease.
The APOE4 gene is associated with an increased risk of developing Alzheimer’s disease. As mentioned earlier, individuals with one copy of APOE4 have a three-fold increased risk, while those with two copies have a twelve-fold increased risk compared to individuals without the gene variant. However, it is important to note that having the APOE4 gene does not guarantee the development of Alzheimer’s. Many individuals with APOE4 do not develop the disease, and conversely, some individuals without APOE4 still develop Alzheimer’s. More and more research points to lifestyle and environmental factors being the major determinants of developing dementia, with someone’s genetic profile being less important (see below).
Researchers are actively investigating the mechanisms by which APOE4 influences the risk of Alzheimer’s. One theory is that APOE4 affects the clearance of beta-amyloid protein, leading to its accumulation and subsequent neurodegeneration. Another theory suggests that APOE4 disrupts the blood-brain barrier, allowing harmful substances to enter the brain and trigger inflammation. Understanding these mechanisms is crucial in developing targeted therapies that can mitigate the impact of APOE4 and potentially prevent or delay the onset of Alzheimer’s disease.
Presence of the APOE4 allele is also associated with increased risk for cerebral amyloid angiopathy (CAA), a condition where amyloid proteins build up on the walls of the arteries in the brain. CAA causes bleeding into the brain (hemorrhagic stroke) and age-related cognitive decline during normal ageing. Types of exercise that are particularly effective in safeguarding against dementia.
While APOE4 is associated with an increased risk of Alzheimer’s, the APOE2 gene variant, on the other hand, appears to have a protective effect. Individuals carrying APOE2 have a lower risk of developing Alzheimer’s compared to those without the gene variant. Although the exact mechanisms behind this protective effect are not yet fully understood, researchers believe that APOE2 may enhance the clearance of beta-amyloid from the brain, preventing its accumulation and subsequent neurodegeneration.
Additionally, studies have shown that APOE2 may have anti-inflammatory properties and promote neuronal survival and repair. These protective effects may help to maintain cognitive function and delay the onset of Alzheimer’s disease. Further research is needed to fully understand the mechanisms by which APOE2 confers this protection and to explore its potential as a therapeutic target.
Among the three forms of APOE genes, APOE3 is considered the most common variant. Unlike APOE4, which is associated with an increased risk, and APOE2, which appears to have a protective effect, APOE3 is considered the neutral variant. Individuals carrying APOE3 are not at a significantly higher or lower risk of developing Alzheimer’s compared to those without the gene variant.
However, it is important to note that APOE3 still plays a role in the pathogenesis of Alzheimer’s disease. While it may not have the same impact as APOE4 or APOE2, variations in APOE3 can influence subtle differences in the risk and progression of the disease. Researchers continue to investigate the specific mechanisms by which APOE3 contributes to Alzheimer’s, aiming to uncover additional insights into the disease’s complexity.
Genetic testing for APOE has become increasingly common. APOE testing can provide individuals with information about their genetic predisposition to Alzheimer’s disease. However, it is important to note that APOE testing is not a diagnostic tool. Having the APOE4 gene does not definitively mean that a person will develop Alzheimer’s, and not having the gene variant does not guarantee protection against the disease.
Genetic counselling is essential for individuals considering APOE testing. Genetic counsellors can help individuals understand the implications of the test results and provide guidance on coping strategies, lifestyle modifications, and potential preventive measures. They can also discuss the limitations of genetic testing and the importance of considering other factors, such as family history and lifestyle, when assessing Alzheimer’s risk.
While APOE genes play a role in Alzheimer’s risk, it is important to remember that they are not the sole determinants. Lifestyle factors also play a crucial role in mitigating the impact of APOE on Alzheimer’s risk. Research has shown that exercise and diet can help reduce the risk and delay the onset of the disease, regardless of genetic predisposition.
Food for the Brain Foundation says that even if you have a gene variant such as ApoE4 it is more like a dimmer switch and can be ‘over-expressed’ or ‘down-regulated’, turned up or dimmed down. That is why approximately half of women with the BRCA gene develop breast cancer and half don’t. The environment the gene is exposed to makes all the difference.
The expression and harmful effects of the ApoE4 gene appear to be down-regulated by eating a low-glycemic load (GL) diet or a more ketogenic diet with specific Mediterranean-style food choices including fatty fish, cruciferous vegetables, olive oil, and low alcohol consumption. Six supplemental nutrients have reasonably good evidence of down-regulating ApoE4. These are omega-3 DHA, B vitamins (B2, B6, B12 and folate) vitamins D3 and K2, quercitin, and resveratrol. This approach to modifying the effects of the genes we inherit with personalised nutrition is a fundamental tenet of orthomolecular medicine, sometimes called personalised, precision, or optimum nutrition.
Study results confirm the beneficial effects of various exercise interventions on global cognition, executive function, and memory function. Exercise, both resistance and aerobic, promotes neurogenesis, better cardiovascular health, and higher ratings of quality of life. Higher frequency (4 times per week rather than twice or three times) and longer duration of exercise (1 hour rather than ½ hour sessions) are associated with better effects.
Research on APOE and its role in Alzheimer’s disease is ongoing, with scientists dedicated to unraveling the complex mechanisms involved. The development of targeted therapies that specifically address the impact of APOE4 is a major focus of current research. Scientists are exploring various approaches, including gene editing techniques, to modify or silence the APOE4 gene and reduce the risk of Alzheimer’s. Down-regulating the gene through diet and supplements as discussed above is something we can start today.
Additionally, researchers are investigating the potential of APOE as a biomarker for early detection and monitoring of Alzheimer’s. By identifying APOE-related changes in the brain, it may be possible to detect the disease in its early stages before significant cognitive decline occurs. This early detection can help initiate interventions and treatments at a time when they are most effective.
Ultimately, understanding the complex relationship between APOE and Alzheimer’s is crucial in developing personalized treatment plans and working towards finding a cure for this disease. Continued research and advancements in our understanding of APOE will bring us closer to effective prevention and treatment strategies, offering hope to millions affected by Alzheimer’s.
—
In conclusion, APOE plays a role in Alzheimer’s disease, with APOE4 being associated with increased risk and APOE2 potentially providing protective effects. Genetic testing and counselling can help individuals assess their risk, but lifestyle factors play a significant role in mitigating the impact of APOE on Alzheimer’s risk. Ongoing research aims to unravel the complex mechanisms involved and pave the way for targeted therapies and early detection strategies. By understanding the intricate relationship between APOE and Alzheimer’s, we can improve the lives of those affected by this challenging disease.
Hearing loss is possibly a risk factor of cognitive decline.
An overview of effective dementia treatments currently available.
Learn about Cognitive Health